Estimating the effect of pravastatin vs usual care under full adherence in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial. [PDF]
Russo RG +6 more
europepmc +1 more source
Comparative Effects of Emerging Lp(a)-Lowering Agents and PCSK9-Directed Therapies on Lipoprotein(a): A Network Meta-Analysis of Randomised Clinical Trials. [PDF]
Zayed JA +4 more
europepmc +1 more source
Increased LDL-C reduction with ezetimibe in ketogenic diet-induced hypercholesterolemia. [PDF]
Gonzalez J +6 more
europepmc +1 more source
Efficacy and Safety of Oral Non-Statin Lipid-Lowering Therapies in Dyslipidaemia: A Systematic Review and Network Meta-Analysis. [PDF]
Hodrob T +6 more
europepmc +1 more source
Apolipoprotein E (apoE) is one of the major protein constituents of chylomicron and very low density lipoprotein (VLDL) remnants and plays a central role as a ligand in the receptor-mediated uptake of these particles by the liver.
Hoffer, M.J.V. +6 more
core
Deciphering the Mechanisms of Statin-Ezetimibe Drug Combinations Using Boolean Logical Modeling and Transcriptomic Data. [PDF]
Wang RS +5 more
europepmc +1 more source
Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab. [PDF]
Tada H, Takamura M.
europepmc +1 more source
Evolocumab in the treatment of refractory chylothorax induced by systemic lupus erythematosus complicated with hyperlipidemia: a case report and literature review. [PDF]
Li X +7 more
europepmc +1 more source
Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. [PDF]
Yao J, Sun Q, Liu D, Lin J, Wang W.
europepmc +1 more source
Longitudinal management and novel pharmacological interactions in a patient with HeFH, 21-OHD, and kawasaki disease: a 6-year clinical follow-up. [PDF]
Zhang Y, Yuan X, Yang X, Chen R.
europepmc +1 more source

